Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet (NYSE: ZBH) launched two foot and ankle trauma implants on Oct 8, 2025: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail. Both products target complex pilon fractures and hindfoot injuries and are available to U.S. foot and ankle specialists.
The Gorilla system provides anatomically contoured dual-column plates, Type II anodized construction, percutaneous guides and long-shaft designs for primary tibiotalar fusion in severely comminuted pilon cases. The Phantom TTC Trauma Nail adds 150/300/350 mm lengths, PRECISION guide technology, up to 8 mm internal compression and Ø7.2/Ø5.0 threaded pegs.
Zimmer Biomet (NYSE: ZBH) completed its acquisition of Monogram Technologies on Oct 7, 2025, adding Monogram's AI-driven semi- and fully autonomous orthopedic robotics to Zimmer Biomet's robotics and navigation portfolio.
Deal consideration converted each Monogram share into $4.04 cash plus non-tradeable contingent value rights (CVRs) entitling holders to up to $12.37 in cash if specified product, regulatory, and revenue milestones are met through 2030. Monogram received FDA 510(k) clearance in March 2025 for a CT-based semi-autonomous TKA system, with commercialization targeted with Zimmer Biomet implants by early 2027. Monogram began a clinical study for a fully autonomous version in July 2025. Zimmer Biomet's ROSA platform is approaching 2,000 installations worldwide and ROSA Knee with OptimiZe has been submitted to the FDA with 510(k) anticipated later in 2025.
Zimmer Biomet (NYSE: ZBH) announced its Q3 2025 earnings webcast and conference call on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release with the quarterly results will be published the same day at 6:30 a.m. ET. The live audio webcast will be available on Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com and will be available for replay after the call.
U.S. and Canada dial-in: (800) 330-6710 with conference ID 7090861. International dial-in: +1 (213) 279-1505 with conference ID 7090861.
Zimmer Biomet (NYSE:ZBH) has received PMDA approval in Japan for the iTaperloc® Complete and iG7™ Hip System, marking a significant breakthrough as the world's first iodine-treated total hip replacement system. The innovative technology inhibits bacterial adhesion and prevents biofilm formation on implant surfaces.
The system addresses Periprosthetic Joint Infection (PJI), which affects 1-2% of primary total joint arthroplasty procedures and carries a mortality rate comparable to breast cancer (11%). The technology, developed by Professor Hiroyuki Tsuchiya, uses a controlled-release iodine layer through advanced anodization and electrophoresis.
This earlier-than-expected approval strengthens Zimmer Biomet's infection management solutions portfolio, combining the clinical heritage of the Taperloc Complete Hip System with the G7 Acetabular System's performance.
Zimmer Biomet (NYSE: ZBH) announced its participation in the American Orthopedic Foot and Ankle Society Annual Conference in Savannah from September 10-13, 2025. The company's subsidiary, Paragon 28, will showcase its comprehensive foot and ankle product portfolio at Booth #421.
Key innovations to be featured include the SMART 28℠ Case Management Portal with AI integration, APEX 3D S™ Stemmed Tibial Implant, Phantom® Fibula Nail System, and several other surgical solutions. The company will also host exclusive events including hands-on training sessions, an innovations dinner, and a networking event on September 11.
Zimmer Biomet (NYSE:ZBH) has strengthened its medical leadership with two key appointments. Dr. Jonathan M. Vigdorchik joins as Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, while Dr. Anand M. Murthi becomes Chief Medical Advisor for Shoulder, Sports, Extremities, and Trauma (S.E.T.).
Both advisors will contribute their clinical expertise to guide product development, enhance medical education initiatives, and serve as strategic liaisons between Zimmer Biomet and the surgical community. Dr. Vigdorchik is from Hospital for Special Surgery in New York City, and Dr. Murthi serves at MedStar Union Memorial Hospital in Baltimore.
Zimmer Biomet (NYSE:ZBH), a global medical technology leader, has announced its quarterly dividend for Q3 2025. The company's Board of Directors approved a cash dividend of $0.24 per share. The dividend will be paid on or around October 31, 2025 to stockholders of record as of the close of business on September 30, 2025.
Zimmer Biomet (NYSE:ZBH) announced its participation in the upcoming Annual Morgan Stanley Healthcare Conference. The company's management team will deliver a presentation on Monday, September 8, 2025, at 8:30 a.m. ET.
Investors can access the live webcast through Zimmer Biomet's Investor Relations website. The presentation will also be available for replay after the conference concludes.
Zimmer Biomet (NYSE:ZBH) reported strong Q2 2025 financial results with net sales of $2.077 billion, up 7.0% year-over-year. The company achieved diluted EPS of $0.77 and adjusted EPS of $2.07, representing a 3.0% increase.
Key highlights include robust growth in U.S. Hips (5.2%) and Knees portfolios, along with significant S.E.T. business growth of 17.3%. The company announced a strategic acquisition of Monogram Technologies to expand its robotics capabilities and formed a partnership with Getinge for Operating Room products distribution.
Zimmer Biomet raised its 2025 guidance, now expecting revenue growth of 6.7-7.7% (reported) and adjusted EPS of $8.10-$8.30, up from previous guidance of $7.90-$8.10.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM) for an upfront payment of $4.04 per share, representing an equity value of approximately $177 million. The deal includes a CVR worth up to $12.37 per share tied to development milestones through 2030.
The acquisition will expand Zimmer Biomet's ROSA® Robotics platform with Monogram's semi- and fully autonomous robotic technologies. Monogram's FDA-cleared CT-based, semi-autonomous AI-navigated total knee arthroplasty technology is expected to be commercialized with Zimmer Biomet implants in early 2027. The deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.
The transaction is expected to be neutral to adjusted EPS in 2025-2027 and accretive thereafter, with revenue growth contribution beginning in 2027. The deal is anticipated to close later in 2025, subject to regulatory and shareholder approvals.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
